New Computed Tomography System Offers Potential Benefits in Cardiac Imaging
The recently launched Scenaria View Focus Edition computed tomography (CT) system features an advanced cardiac motion correction tool that reportedly provides significantly higher temporal resolution than conventional image reconstruction.
Fujifilm Healthcare Americas Corporation has launched the Scenaria View Focus Edition computed tomography (CT) system, a device that may enhance cardiac imaging and reportedly reduces radiation dosing by up to 83 percent.
The Scenaria View Focus Edition, which received 510(k) clearance from the Food and Drug Administration (FDA) in April 2022, may be utilized for a variety of routine and advanced applications, including dual energy exams, interventional radiology procedures and coronary computed tomography angiography (CCTA), according to the company. The new CT system will be showcased at the upcoming Radiological Society of North America (RSNA) annual meeting November 27 to December 1 in Chicago.
Fujifilm said a unique feature of the Scenaria View Focus Edition CT system is the Cardio StillShot, a cardiac motion correction tool, which captures two data sets in each scan that are subsequently compared to help detect and correct heart motion. The Cardio StillShot allows temporal resolution of 28 milliseconds with final images in comparison to 175 milliseconds with conventional image reconstruction, according to Fujifilm.
In comparison to conventional filtered back projection image reconstruction, Fujifilm said the Scenaria View Focus Edition’s use of iterative reconstruction reduces radiation dosing by up to 83 percent and reduces image noise by up to 90 percent.
“Providers need a powerful CT system that gives them the diagnostic confidence to make the right treatment decisions for their patients,” noted Mark Silverman, the director of marketing for CT at Fujifilm Healthcare Americas Corporation. “Fujifilm’s Scenaria View Focus Edition makes this possible through the convergence of high temporal resolution, enhanced workflow that reduces examination time, and advanced dose reduction capabilities.”
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
